Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

 

Clinical Trials

liver cancer treatment - nurse holding clipboard with mature male patient

If you would like more information on Liver, Bile Duct and Gallbladder Cancer Clinical Trials offered at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, please contact: 410-955-8964, Option #2.

Current trial listing:

Hepatocellular Carcinoma

J18118 - The effect of CTLA4/PDL-1 Blockade following drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with intermediate stage of HCC using Durvalumab (MEDI4736) and Tremelimumab
NCT03638141

 

J19140 - A pilot study of a DNAJB1-PRKACA fusion kinase peptide vaccine combined with Nivolumab and Ipilimumab for patients with fibrolamellar hepatocellular carcinoma
NCT04248569

 

J2003 - An Open-label, Multi-center, Phase I/IIa Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid encoded IL 12 (INO-9012) in Combination with Pembrolizumab (MK-3475) in Subjects with Advanced Hepatocellular Carcinoma
NCT04251117

 

J2007 - A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
NCT03829436

 

J20121 - Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients with Potentially Resectable Hepatocellular Carcinoma (HCC)
NCT04658147

Coming Soon:

J2121-A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK 1308A (Co-formulated MK 1308/MK 3475) in Combination with Lenvatinib (E7080/MK 7902) in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma.
NCT04740307

Biliary Tract Cancers: Cholangiocarcinoma/Bile duct Cancer/Gallbladder Cancer

J19108 - A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without M7824 (bintrafusp alfa) as First-line Treatment of Biliary Tract Cancer
NCT4066491

 

J2007 - A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors.
NCT03829436

 

J2031 - J2031: A Phase II Study of durvalumab (MEDI4736) in combination with a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients with Intrahepatic Cholangiocarcinoma.
NCT04301778

 

J2075 - An Open-Label Expanded Access Program of Futibatinib (TAS-120) In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements. NCT04507503

 

J2089 - A Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations (LOXO-IDH-20002)
NCT04521686

 

ETCTN10129 - A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors.
NCT03212274

 

ETCTN10222 - A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors.
NCT03878095

Coming Soon

ETCTN10476- A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) with or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers

 

Search For Cancer Clinical Trials

back to top button